Replimune Group, Inc. Reports Net Loss of $49.6 Million for the Second Quarter of 2023
Revenue Stands at $6.3 Million for Replimune Group, Inc. in Q2 2023
By USInMinutes
Published - Aug 03, 2023, 04:16 PM ET
Last Updated - Aug 03, 2023, 04:16 PM EDT
Replimune Group, Inc.(PERL), a leading biotechnology compa ny, released its condensed consolidated financial statements for the three months ended June 30, 2023. The report shows a net loss of $49.6 million for the quarter, accompanied by revenue of $6.3 million.
Net Loss of $49.6 Million
The company's net loss for the second quarter of 2023 was $49.6 million, compared to a net loss of $42.3 million for the same period in 2022. This represents a year-over-year increase in net loss, reflecting the continued investments in research and development as well as selling, general, and administrative expenses.
Revenue of $6.3 Million
